Although tumors in the anti-PD1 group showed slower growth, the change from baseline was not statistically significant (p = 0.0775), likely due to the large variation of responses to treatment, small sample sizes, and termination of treatment due to ethical endpoints (tumor size > 20 mm, severe ulceration, or disease-related mortality). This evidence concerns the gene PDCD1 and neoplasm.